Item 1.01 Entry Into a Material Definitive Agreement.

On February 21, 2022, Arteris IP (Hong Kong) Ltd. ("AHK"), a wholly-owned subsidiary of Arteris, Inc. ("Arteris" or the "Company"), entered into a Share Purchase and Shareholders Agreement (the "SPA") by and among AHK, Arteris Semiconductor Technology (Nanjing) Co., Ltd., a wholly-owned subsidiary of Arteris ("Arteris Nanjing"), TransChip Technology (Nanjing) Co., Ltd., a wholly-owned subsidiary of Arteris Nanjing ("Transchip"), SME Development (Shaoxing) Venture Fund, LLP, a limited partnership organized in China ("SME"), Jiaxing Luojia Chuangzhi Investment Partnership Enterprise (Limited Partnership), a limited partnership organized in China ("Luojia"), Gongqing City Guinie Zhuyu No. 3 Investment Partnership (Limited Partnership), a limited partnership organized in China ("Guinie", together with SME and Luojia, the "Investors"), and Ningbo Transchip Information Consulting Partnership (Limited Partnership) ("Management Co"), pursuant to which, and on the terms and subject to the conditions thereof, AHK, the Investors and Management Co will subscribe for the increased registered capital of Transchip in the aggregate amount of RMB196,500,000. In particular, pursuant to the SPA and the agreements contemplated therein, the contributions and resulting approximate registered capital holding percentages summarized below are as follows:



           i.   The registered capital of Transchip will be increased from
                RMB200,000 to RMB196,500,000 (the "Capital Increase"), and the
                increased portion of the registered capital will be subscribed by
                AHK, the Investors and Management Co as follows: (a) (i) RMB
                77,330,000 will be subscribed by AHK and be contributed in-kind by
                way of a technology license by AHK pursuant to the Technology
                License Agreement (as defined below), (ii) RMB1,700,000 will be
                subscribed by AHK and contributed in cash, and (iii) initial
                registered capital in the amount of RMB200,000 in Transchip will
                be transferred by Arteris Nanjing to AHK, following which AHK's
                aggregate capital contribution to Transchip will represent 40.321%
                of the registered capital of Transchip; (b) SME will contribute
                RMB 30,000,000 in cash, representing 15.267% of the registered
                capital of Transchip; (c) Luojia will contribute RMB 20,000,000 in
                cash, representing 10.178% of the registered capital of Transchip;
                (d) Guinie will contribute RMB26,500,000 in cash, representing
                13.486% of the registered capital of Transchip; and (e) Management
                Co will subscribe for 20.748% of the registered capital of
                Transchip for RMB 40,770,000, which will be reserved for
                Transchip's employee option plan.



           ii.  Pursuant to a technology license agreement (the "Technology
                License Agreement"), AHK will license to Transchip certain uses of
                specific licensed products enabling Transchip to conduct its SoC
                chip platform and automotive system-level IP business in
                automotive application(s), including, among others, a 5-year
                design term for FlexNoC v.4.x, FlexWay v.4.x, CodaCache 1.x, Ncore
                v.3.x and Resilience and AI package (without standalone licensing
                nor sublicensing rights) by AHK to Transchip; upon expiry of the
                term, the parties may discuss a possible new license for a new
                5-year design term.

Following the consummation of the foregoing transactions, and subject to closing terms and conditions in the SPA, it is currently anticipated that AHK will hold a 40.321% equity interest in Transchip and that Transchip will receive aggregate cash proceeds from the Investors of RMB76,500,000 (or approximately $12 million at current RMB-USD exchange rates), indicative of a post-money valuation of RMB 196,500,000 (or approximately $35.6 million at current RMB-USD exchange rates). Arteris expects Transchip to use the proceeds from the Capital Increase for development of products using the licensed technologies from AHK.

According to the SPA which also provides on shareholder rights, governance and management of Transchip, AHK will be entitled to nominate one individual on Transchip's three-person board of directors. It is currently contemplated that the board of directors of Transchip will initially be comprised of an individual nominated by SME, an individual nominated by AHK, and an individual nominated by Management Co.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses